Pharmacological and safety evaluation of CIGB-300, a casein kinase 2 inhibitor peptide, administered intralesionally to patients with cervical cancer stage IB2/II by JL, Soriano-García, A, López-Díaz, M, Solares-Asteasuainzarra, I, Baladrón-Castrillo, N, Batista-Albuerne, I, García-García, L, González-Méndez, Y, Perera-Negrín, CM, Valenzuela-Silva, AP, Pedro, LS, Quevedo-Sotolongo, I, Hernández-González, JM, Silveira-Pablos, A, Chong-López, DF, Alonso, JY, Gómez RE, Renault, P, Perrin, H, Sigman, S, Gold, SE, Perea-Rodríguez, BE, Acevedo-Castro, L, Herrera-Martínez, PA, López-Saura

Get full text